Veracyte will present new results that showcase the ability of the Envisia Genomic Classifier to provide reliable data that helps physicians diagnose interstitial lung disease (ILD) — including idiopathic pulmonary fibrosis (IPF) — at CHEST 2018 meeting. Veracyte also will present new results about the capability of the…
I am writing this column from my hospital room, and I’m feeling pretty frustrated. As I was rushing into the grocery store this evening with my oxygen tank strapped to my back and a million things on my mind, I unfortunately didn’t notice the person smoking right outside…
A recent study in mice shows that endometrial regenerative cells (ERCs) can ease some of the common symptoms of idiopathic pulmonary fibrosis (IPF). Titled “Human Endometrial Regenerative Cells Attenuate Bleomycin-Induced Pulmonary Fibrosis in Mice,” the study was recently published in the journal Stem Cells International. Therapeutic…
Treatment with Esbriet (pirfenidone) or Ofev (nintedanib) significantly slowed the progression of idiopathic pulmonary fibrosis (IPF) in a real-life clinical setting, an Italian study reported. The study, “Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre” was published in the journal…
I understand that it is uncommon to see a young adult wearing supplemental oxygen and using a wheelchair due to fatigue. It might spark a passerby’s curiosity about what has made this young person’s lungs so sick that they can’t breathe efficiently. I understand curiosity, but as…
Samumed and United Therapeutics announced an exclusive license agreement for North American rights to Samumed’s investigational therapy SM04646 to treat idiopathic pulmonary fibrosis (IPF). Under the agreement, United Therapeutics will pay Samumed $10 million up-front, plus up to $340 million in developmental milestones in addition to other…
Treating one’s self with tender care is especially important to pulmonary fibrosis patients and their families. Medical tests, clinic visits, long-term illness management, and a shortened lifespan are difficult, unpleasant, and stressful experiences. We continue to grieve and adjust as our lungs worsen. It is important to respond…
Corbus Pharmaceuticals has acquired from Jenrin Discovery more than 600 compounds designed to target the endocannabinoid system, including CRB-4001 for the treatment of fibrotic diseases affecting the lungs, liver, heart, and kidney. The endocannabinoid system is associated with the resolution (or shutting off) of the inflammatory response, which…
I hope I never take my ability to travel for granted. The world is a beautiful place, and despite my diagnosis of idiopathic pulmonary fibrosis (IPF), I intend to see as much of it as possible while I still can. Recently, I spent time on the east coast…
Roivant Sciences has launched a new company whose focus is developing potential treatments for serious respiratory diseases. Named Respivant Sciences, it will begin by advancing RVT-1601 as an investigative therapy for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). RVT-1601, formerly known as PA101, is a novel formulation…
Get regular updates to your inbox.
